Alan Glicklich - 24 Jun 2025 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Role
Director
Signature
/s/ John Dunn, Attorney-in-Fact
Issuer symbol
CALC
Transactions as of
24 Jun 2025
Net transactions value
$0
Form type
4
Filing time
26 Jun 2025, 18:23:49 UTC
Previous filing
16 Jan 2025
Next filing
14 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Glicklich Alan Director C/O CALCIMEDICA, INC., 505 COAST S. BLVD, #307, LA JOLLA /s/ John Dunn, Attorney-in-Fact 26 Jun 2025 0001823197

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CALC Director Stock Option (Right to Buy) Award $0 +10,000 $0.000000 10,000 24 Jun 2025 Common Stock 10,000 $1.53 Direct F1, F2
transaction CALC Director Stock Option (Right to Buy) Award $0 +4,166 $0.000000 4,166 24 Jun 2025 Common Stock 4,166 $1.53 Direct F1, F3
transaction CALC Director Stock Option (Right to Buy) Award $0 +15,000 $0.000000 15,000 24 Jun 2025 Common Stock 15,000 $1.53 Direct F1, F4
transaction CALC Director Stock Option (Right to Buy) Award $0 +10,000 $0.000000 10,000 24 Jun 2025 Common Stock 10,000 $1.65 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.
F2 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025.
F3 Immediately exercisable.
F4 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025.
F5 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders.